Items Tagged ‘foundation medicine’

December 7, 2017

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available


The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare & Medicaid Services (CMS) the latter proposed coverage of the F1CDx test under the new […]

View full entry

Tags: biomarker testing, CMS, foundation medicine, General, genomic testing, immunotherapy, KEYNOTE-028, News, Other News Topics (not Types of Cancer), PD-L1 positive, Precision Cancer Medicine, SCLS